|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004927,
umls-concept:C0007102,
umls-concept:C0016360,
umls-concept:C0021734,
umls-concept:C0023413,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0087111,
umls-concept:C0282461,
umls-concept:C0679729,
umls-concept:C1518578,
umls-concept:C1522673
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-6-27
|
|
pubmed:abstractText |
It has been shown in randomized studies that adjuvant treatment with the combination of fluorouracil (FU) and levamisole reduced the risk of recurrence and deaths of patients with stage III colon cancer. Pharmacological studies of FU led to its use in combination with a number of modulating agents including interferon-alpha and leucovorin (LV) that appear to enhance its activity in vitro. Furthermore, a meta-analysis suggested that the combination of FU with LV increased the response rate as compared to FU monotherapy in patients with advanced colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:AravantinosGG,
pubmed-author:BasdanisGG,
pubmed-author:BousoulegasAA,
pubmed-author:BriassoulisEE,
pubmed-author:DafniUU,
pubmed-author:DokmetzioglouJJ,
pubmed-author:FountzilasGG,
pubmed-author:GiannoulisEE,
pubmed-author:HatzitheoharisGG,
pubmed-author:KarvounisNN,
pubmed-author:KatsohisCC,
pubmed-author:KonstantarasCC,
pubmed-author:KosmidisPP,
pubmed-author:NenopoulouEE,
pubmed-author:PapavramidisSS,
pubmed-author:PavlidisNN,
pubmed-author:SkarlosDD,
pubmed-author:ZisiadisAA
|
|
pubmed:copyrightInfo |
Copyright 2000 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
227-36
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10765125-Adult,
pubmed-meshheading:10765125-Aged,
pubmed-meshheading:10765125-Antimetabolites, Antineoplastic,
pubmed-meshheading:10765125-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10765125-Colonic Neoplasms,
pubmed-meshheading:10765125-Disease-Free Survival,
pubmed-meshheading:10765125-Female,
pubmed-meshheading:10765125-Fluorouracil,
pubmed-meshheading:10765125-Humans,
pubmed-meshheading:10765125-Interferon-alpha,
pubmed-meshheading:10765125-Leucovorin,
pubmed-meshheading:10765125-Male,
pubmed-meshheading:10765125-Middle Aged,
pubmed-meshheading:10765125-Neoplasm Staging,
pubmed-meshheading:10765125-Prognosis,
pubmed-meshheading:10765125-Recombinant Proteins,
pubmed-meshheading:10765125-Survival Analysis,
pubmed-meshheading:10765125-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece. fountzil@med.auth.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
